ID   ALVA-31
AC   CVCL_4737
SY   ALVA 31; ALVA31; American Lake VA-31
DR   BTO; BTO:0003850
DR   BioSample; SAMN03151889
DR   cancercelllines; CVCL_4737
DR   Wikidata; Q54749373
RX   CelloPub=CLPUB00698;
RX   PubMed=7681207;
RX   PubMed=8561862;
RX   PubMed=11304728;
RX   PubMed=12725112;
RX   PubMed=20143388;
CC   Problematic cell line: Contaminated. Shown to be a PC-3 derivative (PubMed=11304728; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from the tumor mass removed during a radical prostatectomy in a patient with well differentiated, stage B2, adenocarcinoma of the prostate.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00173.
CC   Population: Caucasian.
CC   Doubling time: ~26 hours (PubMed=7681207); 23 hours (PubMed=8561862).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
ST   Source(s): PubMed=11304728
ST   Amelogenin: X
ST   D13S317: 11
ST   D18S51: 15
ST   D21S11: 29,31.2
ST   D3S1358: 16
ST   D5S818: 13,14
ST   D7S820: 8,11,12
ST   D8S1179: 13
ST   FGA: 24
ST   vWA: 17
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
RX   PubMed=7681207; DOI=10.1002/pros.2990220202;
RA   Loop S.M., Rozanski T.A., Ostenson R.C.;
RT   "Human primary prostate tumor cell line, ALVA-31: a new model for
RT   studying the hormonal regulation of prostate tumor cell growth.";
RL   Prostate 22:93-108(1993).
RX   PubMed=8561862; DOI=10.1002/(SICI)1098-2744(199601)15:1<18::AID-MC4>3.0.CO;2-O;
RA   Mehta P.P., Lokeshwar B.L., Schiller P.C., Bendix M.V., Ostenson R.C.,
RA   Howard G.A., Roos B.A.;
RT   "Gap-junctional communication in normal and neoplastic prostate
RT   epithelial cells and its regulation by cAMP.";
RL   Mol. Carcinog. 15:18-32(1996).
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).